London, UK, and Cambridge, MA, 17 July 2008 - Antisoma plc (LSE: ASM; USOTC: ATSMY) today announced that its Tumour-Vascular Disrupting Agent, ASA404, will enter a second pivotal phase III trial this year. The ATTRACT-2 (Anti-vascular Targeted Therapy: Researching ASA404 in Cancer Treatment-2) trial will be conducted by Antisoma’s partner, Novartis, and will evaluate ASA404 as a second-line treatment for non-small cell lung cancer (NSCLC). A separate, ongoing phase III trial (ATTRACT-1) is testing ASA404 as a first-line treatment for NSCLC.
